Chemed
CHE
501.45
-8.39
-1.65%
Chemed
US · CHE
#1837 by market cap
Listed 1970
501.45
-8.39
-1.65%
Live - 5344 symbols - heartbeat 323s ago
· 2026-10-07 19:54
After-hours
501.50
+0.01%
- Market cap
- 6.53B
- P/E (TTM)i
- 25.22
- P/Bi
- 7.86
- EPSi
- 18.34
- Div yieldi
- 0.48%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on CHE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 12.09, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.06% YoY
Margins
- Gross margin
- 32.54%
- Operating margin
- 13.48%
- Net margin
- 10.48%
Key ratios & quality
- PEG ratioi
- 12.35
- Altman Z-Scorei
- 12.09
PEG uses trailing P/E against the 3-year net income growth rate (2.04%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78B | 1.94B | 2.08B | 2.14B | 2.13B | 2.26B | 2.43B | 2.53B |
| Gross profit | 555.00M | 617.43M | 701.39M | 769.80M | 765.09M | 798.82M | 854.35M | 823.18M |
| Selling & admin expenses | 271.21M | 305.71M | 330.22M | 366.73M | 358.73M | 395.12M | 424.36M | 417.19M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 244.93M | 266.51M | 389.68M | 344.03M | 347.19M | 342.83M | 366.94M | 341.16M |
| Pretax profit | 239.60M | 261.61M | 395.99M | 350.31M | 329.68M | 350.37M | 399.47M | 355.78M |
| Tax | 34.06M | 41.69M | 76.52M | 81.76M | 80.06M | 77.86M | 97.47M | 90.54M |
| Net profit | 205.54M | 219.92M | 319.47M | 268.55M | 249.62M | 272.51M | 302.00M | 265.24M |
| Basic EPS | 13 | 14 | 20 | 17 | 17 | 18 | 20 | 18 |
| Diluted EPS | 12.23 | 13.31 | 19.48 | 16.85 | 16.53 | 17.93 | 19.89 | 18.34 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 646.94M | 618.80M | 624.90M | 639.34M | 657.51M | 673.25M |
| Gross profit | 216.41M | 184.69M | 196.91M | 225.17M | 215.76M | 221.47M |
| Selling & admin expenses | 105.59M | 100.32M | 105.78M | 105.50M | 114.32M | 115.20M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 94.76M | 68.08M | 74.75M | 103.56M | 84.58M | 89.20M |
| Pretax profit | 95.67M | 71.12M | 83.54M | 105.45M | 88.84M | 91.33M |
| Tax | 23.92M | 18.62M | 19.31M | 28.69M | 22.54M | 23.63M |
| Net profit | 71.76M | 52.49M | 64.24M | 76.75M | 66.30M | 67.70M |
| Basic EPS | 5 | 4 | 4 | 5 | 5 | 5 |
| Diluted EPS | 4.86 | 3.57 | 4.46 | 5.48 | 4.84 | 5.13 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 159.84M | 190.67M | 329.40M | 230.29M | 272.61M | 500.84M | 394.75M | 302.62M |
| Cash & ST investments | 4.83M | 6.16M | 162.68M | 32.90M | 74.13M | 263.96M | 178.35M | 74.52M |
| Inventory | 5.71M | 7.46M | 7.10M | 10.11M | 10.27M | 12.00M | 8.19M | 7.54M |
| Total assets | 975.53M | 1.27B | 1.43B | 1.34B | 1.44B | 1.67B | 1.67B | 1.54B |
| Total current liabilities | 191.67M | 262.22M | 299.11M | 302.40M | 297.21M | 312.05M | 285.70M | 287.13M |
| Short-term debt | -- | 39.28M | 36.20M | 37.91M | 44.00M | 38.64M | 42.31M | 40.89M |
| Long-term debt | 89.20M | 90.00M | -- | 185.00M | 92.50M | -- | -- | -- |
| Total liabilities | 384,195,000.00 | 541,709,000.00 | 533,711,000.00 | 719,450,000.00 | 643,297,000.00 | 560,219,000.00 | 549,582,000.00 | 558,784,000.00 |
| Total equity | 591.33M | 726.61M | 901.20M | 623.27M | 798.72M | 1.11B | 1.12B | 979.41M |
| Retained earnings | 1.23B | 1.43B | 1.72B | 1.97B | 2.20B | 2.45B | 2.72B | 2.96B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 502.39M | 491.38M | 395.24M | 302.62M | 274.06M | 291.24M |
| Cash & ST investments | 173.88M | 249.90M | 129.75M | 74.52M | 16.86M | 40.22M |
| Inventory | 7.79M | 9.15M | 8.24M | 7.54M | 7.21M | 7.63M |
| Total assets | 1.73B | 1.72B | 1.62B | 1.54B | 1.54B | 1.58B |
| Total current liabilities | 290.56M | 263.89M | 292.04M | 287.13M | 321.42M | 319.85M |
| Short-term debt | 42.98M | 43.70M | 42.01M | 40.89M | 41.29M | 41.28M |
| Long-term debt | -- | -- | -- | -- | 91.20M | 140.00M |
| Total liabilities | 544,753,000.00 | 519,362,000.00 | 546,936,000.00 | 558,784,000.00 | 687,821,000.00 | 749,075,000.00 |
| Total equity | 1.18B | 1.20B | 1.08B | 979.41M | 847.99M | 830.51M |
| Retained earnings | 2.79B | 2.83B | 2.89B | 2.96B | 3.01B | 3.07B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 287.14M | 301.25M | 489.29M | 308.60M | 309.89M | 330.30M | 417.50M | 388.27M |
| Depreciation & amortization | 38.86M | 45.21M | 56.58M | 59.05M | 59.17M | 60.87M | 63.05M | 64.84M |
| Free cash flow | 234.27M | 248.23M | 430.46M | 249.92M | 252.56M | 273.45M | 367.97M | 325.48M |
| Dividends paid | -18.66M | -19.79M | -21.08M | -22.02M | -22.02M | -23.50M | -27.09M | -31.70M |
| Stock buybacks / issuance | -158.88M | -92.63M | -175.59M | -576.04M | -114.52M | -67.70M | -361.39M | -431.50M |
| Ending cash balance | 4.83M | 6.16M | 162.68M | 32.90M | 74.13M | 263.96M | 178.35M | 74.52M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 32.74M | 138.61M | 83.39M | 133.53M | 88.22M | 84.81M |
| Depreciation & amortization | 16.02M | 16.26M | 16.23M | 16.33M | 16.87M | 16.99M |
| Free cash flow | 19.46M | 122.80M | 66.03M | 117.19M | 71.10M | 69.29M |
| Dividends paid | -7.33M | -7.22M | -8.65M | -8.50M | -8.17M | -7.88M |
| Stock buybacks / issuance | -33.22M | -42.95M | -180.78M | -174.56M | -190.04M | -97.48M |
| Ending cash balance | 173.88M | 249.90M | 129.75M | 74.52M | 16.86M | 40.22M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 36.33 | 33.37 | 39.25 | 35.23 | 35.11 | 28.59 | 27.12 | 25.28 |
| ROA %i | 21.69 | 19.60 | 23.64 | 19.34 | 17.93 | 17.52 | 18.10 | 16.54 |
| ROIC %i | 31.90 | 26.87 | 32.41 | 27.19 | 25.38 | 23.39 | 23.17 | 21.82 |
| 5-year avg ROE %i | 24.13 | 26.40 | 29.67 | 32.53 | 35.86 | 34.31 | 33.06 | 30.27 |
| EBIT margin %i | 13.72 | 13.73 | 19.16 | 16.46 | 15.66 | 15.61 | 16.50 | 14.13 |
| FCF / sales %i | 13.14 | 12.80 | 20.70 | 11.68 | 11.83 | 12.08 | 15.13 | 12.86 |
| Current ratioi | 0.83 | 0.73 | 1.10 | 0.76 | 0.92 | 1.61 | 1.38 | 1.05 |
| Quick ratioi | 0.65 | 0.57 | 0.97 | 0.56 | 0.72 | 1.43 | 1.22 | 0.90 |
| Debt / assetsi | 9.14 | 17.03 | 9.44 | 24.10 | 17.13 | 8.36 | 8.44 | 9.35 |
| LT debt / equityi | 15.08 | 24.31 | 11.01 | 45.83 | 25.42 | 9.10 | 8.81 | 10.50 |
| Interest coveragei | 49.02 | 58.69 | 169.15 | 188.53 | 72.92 | 113.73 | 225.42 | 204.30 |
| Revenue CAGR (3Y) %i | 4.92 | 7.13 | 7.66 | 6.27 | 3.27 | 2.88 | 4.36 | 5.82 |
| Net income CAGR (3Y) %i | 23.07 | 26.46 | 48.19 | 9.32 | 4.31 | -5.16 | 3.99 | 2.04 |
| FCF CAGR (3Y) %i | 22.52 | 37.44 | 63.66 | 2.18 | 0.58 | -14.04 | 13.76 | 8.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 26.11 | 24.14 | 24.11 | 25.28 | 25.60 | 27.11 |
| ROA %i | 17.88 | 16.82 | 16.43 | 16.54 | 15.93 | 16.68 |
| ROIC %i | 22.64 | 20.98 | 20.93 | 21.82 | 21.20 | 22.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.57 | 15.51 | 14.71 | 14.13 | 13.81 | 14.35 |
| FCF / sales %i | 12.66 | 14.79 | 14.24 | 12.86 | 14.84 | 12.47 |
| Current ratioi | 1.73 | 1.86 | 1.35 | 1.05 | 0.85 | 0.91 |
| Quick ratioi | 1.58 | 1.65 | 1.18 | 0.90 | 0.72 | 0.72 |
| Debt / assetsi | 8.40 | 8.47 | 8.71 | 9.35 | 15.43 | 18.66 |
| LT debt / equityi | 8.64 | 8.50 | 9.24 | 10.50 | 23.07 | 30.53 |
| Interest coveragei | 244.86 | 229.47 | 215.38 | 204.30 | 181.52 | 113.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- VITAS is the largest reported line at 65.85% of revenue, across 2 reported segments.
- Roto-Rooter follows at 34.15%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
VITAS65.85%
Roto-Rooter34.15%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.